Home > Search Results

Results: 1 to 20 of 27

Adjuvant (supplementary treatment after initial treatment) platinum‐based anti‐cancer drugs for early stage cervical cancer

Cervical cancer is the second most common cancer among women. Most women with early stage cervical cancer (stages I to IIA) are cured with surgery or, radiotherapy, or both. Radiotherapy uses high energy x‐rays to damage tumour cells. Chemotherapy (anti‐cancer) drugs use different ways to stop tumour cells dividing so they stop growing or they die.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Follow‐up strategies for participants treated for non‐metastatic colorectal cancer

Colorectal cancer affects about 1 in 20 people in developed countries. Most patients (about two thirds) have curable disease. Follow‐up after curative treatment usually means visits to the doctor as well as having some tests. Many people believe that follow‐up saves lives, but we are not sure how often the patient should see the doctor and what tests they should have, and when.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Prevention of blood clots in non‐hospitalised cancer patients receiving chemotherapy

Cancer patients are more likely than people without cancer to develop blood clots in their veins (known as venous thromboembolism). Chemotherapy further increases this risk. Yet a number of factors specific to the cancer, such as the bleeding tendency at the site of the cancer, or a relative decrease in the number of platelets in the blood (thrombocytopenia) caused by chemotherapy can increase the likelihood that cancer patients will have bleeding complications with medicines used to prevent and treat blood clots (anticoagulants). This systematic review looked at the effectiveness and safety of anticoagulants when used to prevent blood clots in cancer patients receiving chemotherapy.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2017

Systematic Guideline Search and Appraisal, as Well as Extraction of Relevant Recommendations, for the DMP "Breast Cancer" [Internet]

The aim of this study was to specify a potential need for updating and supplementation of the existing DMP “breast cancer” by means of a systematic search for new evidence-based guidelines relevant to the subject and by the synthesis of the guideline recommendations.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: May 20, 2014

Ways of helping children with cancer to take part in decisions about their health care

We reviewed the evidence about what helps children with cancer to take part in decisions about their health care. We found no studies.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Assessment of the Benefit of Screening in Persons Under 55 Years of Age with a Family History of Colorectal Cancer [Internet]

The research question of the report was divided into several sub-goals:

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: May 29, 2013

Nipple‐ and areola‐sparing mastectomy for the treatment of breast cancer

We reviewed the evidence about the effectiveness and safety of nipple‐sparing mastectomy (that is, removing the breast tissue but preserving the entire skin, nipple and areola) compared to traditional mastectomy (that is, removing the skin that overlies the breast including nipple and areola) or skin‐sparing mastectomy (that is, removing the breast tissue including the breast and areola but preserving all the skin envelope).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Education for the management of cancer‐related fatigue

This systematic review sought to find out how well educational interventions worked for managing cancer‐related fatigue.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Radium-223 for Patients with Castration Resistant Prostate Cancer with Bone Metastases: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines [Internet]

The aim of this report is to review the clinical effectiveness, cost-effectiveness, and evidence-based guidelines of radium-223 (Ra-223) in patients with bone metastatic castration-resistant prostate cancer (mCRPC).

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: October 31, 2016

Eribulin -- Benefit Assessment According to §35a Social Code Book V [Internet]

The benefit assessment of eribulin was carried out in accordance with the approved therapeutic indication of “Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane, unless patients were not suitable for these treatments”.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: January 30, 2012

Aflibercept (Zaltrap) -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report is to assess the added benefit of aflibercept in combination with a chemotherapy consisting of irinotecan / 5-fluorouracil / folinic acid (FOLFIRI) in comparison with FOLFIRI as appropriate comparator therapy (ACT) in adult patients with metastatic colorectal cancer (mCRC) that has progressed during or after an oxaliplatin-containing regimen. The comparator therapy chosen by the company concurs with the ACT specified by the Federal Joint Committee.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: May 29, 2013

Cabazitaxel -- Benefit Assessment According to §35a Social Code Book V [Internet]

The present benefit assessment relates to the treatment of metastatic hormone-refractory prostate cancer (mHRPC) in patients previously treated with a docetaxel-containing treatment regimen and was carried out separately for 2 patient populations.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: January 12, 2012

Nintedanib -- Benefit Assessment According to §35a Social Code Book 4 [Internet]

The aim of this report is to assess the added benefit of nintedanib in combination with docetaxel in comparison with the appropriate comparator therapy (ACT) in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: March 30, 2015

Enzalutamide (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book [Internet]

The aim of the present report was to assess the added benefit of enzalutamide versus the appropriate comparator therapy (ACT) for treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) in whom chemotherapy is not yet clinically indicated.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: March 30, 2015

Trastuzumab Emtansine -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of the present report is to assess the added benefit of trastuzumab emtansine in patients with human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior treatment for locally advanced or metastatic disease, or developed disease recurrence during or within 6 months of completing adjuvant therapy.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: March 28, 2014

Afatinib -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this benefit assessment is to assess the added benefit of afatinib in epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-naive adult patients with locally advanced and / or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: February 13, 2014

Curation vs. Palliation: An Attempt to Clarify Terms [Internet]

The aim of the project reported here was to investigate whether publications of RCTs on patients with advanced cancer take into account aspects of the end of life, the corresponding terminology and the relevance of palliative care needs of these patients. Based on the publications of treatment studies, the specific aims were to investigate if

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: April 15, 2014

Biologics or tofacitinib alone for people with rheumatoid arthritis who had not improved with traditional disease‐modifying anti‐rheumatic drugs

In people with rheumatoid arthritis (RA), the immune system, which normally fights infection, attacks the joint lining making joints inflamed, swollen, stiff and painful. We looked for trials of biologics (large molecules administered by injection) or tofacitinib (small molecules given by mouth) in people with RA.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Radium-223 Dichloride -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report is to assess the added benefit of radium-223 dichloride (hereinafter referred to as “radium-223”) in comparison with the appropriate comparator therapy (ACT) in patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: March 28, 2014

Abiraterone Acetate -- Benefit Assessment According to §35a Social Code Book V [Internet]

The present benefit assessment relates to the treatment of metastatic castration-resistant prostate cancer (mCRPC) of adult men and was carried out separately for 2 patient populations.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: December 29, 2011

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...